SCHEMBL6071604

SCHEMBL6071604

N#Cc1ccc2[nH]c3c(c2c1)CCc1c[nH]nc1-3

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPK10 P53779 7/20 0.61
RIPK1 Q13546 5/20 0.61
GSK3B P49841 8/20 0.46
CDK5 Q00535 8/20 0.46
CDK5R1 Q15078 8/20 0.46
CCNB2 O95067 5/20 0.46
CDK1 P06493 5/20 0.46
CCNB1 P14635 5/20 0.46
CCNB3 Q8WWL7 5/20 0.46
GSK3A P49840 4/20 0.46
CCNA2 P20248 2/20 0.46
CDK2 P24941 2/20 0.46
CCNA1 P78396 2/20 0.46
AR P10275 3/20 0.41
CHUK O15111 1/20 0.39
KDM4E B2RXH2 2/20 0.38
MEN1 O00255 2/20 0.38
ALDH1A1 P00352 2/20 0.38
LMNA P02545 2/20 0.38
MAPT P10636 2/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6070946 0.90 MAPK10 (0.61) MAPK10RIPK1GSK3BCDK5CDK5R1
SCHEMBL6071270 0.81 PRKD1 (0.47) MAPK10RIPK1GSK3BCDK5CDK5R1
SCHEMBL6070722 0.81 MAPK10 (0.59) MAPK10RIPK1GSK3BCDK5CDK5R1
SCHEMBL6070686 0.79 MAPK10 (0.62) MAPK10RIPK1GSK3BCDK5CDK5R1
SCHEMBL6070835 0.79 MPL (0.50) MAPK10RIPK1GSK3BCDK5CDK5R1
SCHEMBL6070734 0.77 GSK3B (0.47) MAPK10RIPK1GSK3BCDK5CDK5R1
SCHEMBL6070951 0.76 MAPT (0.55) GSK3BCDK5CDK5R1CCNB2CDK1
SCHEMBL6070802 0.74 MEN1 (0.49) MAPK10RIPK1GSK3BCDK5CCNB2
SCHEMBL6071325 0.73 MAP2K1 (0.43) MAPK10RIPK1KDM4EMEN1ALDH1A1
SCHEMBL6071032 0.73 MAPK10 (0.59) MAPK10RIPK1KDM4EMEN1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20060264493-A1 Tetracyclic pyrazole derivatives as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them PFIZER ITALIA S.R.L. (IT) 2006-11-23 US claimed
US-20060264493-A1 Tetracyclic pyrazole derivatives as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them PFIZER ITALIA S.R.L. (IT) 2006-11-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060264493-A1 Tetracyclic pyrazole derivatives as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them MAP3K1, MAP3K19, MAP3K20 MAPK10 387/4885RIPK1 131/4885GSK3B 463/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.